Korro Bio receives ODD from U.S. FDA for AATD

Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency, AATD. “Receiving orphan drug designation from the FDA underscores the growing need for new treatments for patients living with AATD,” said Kemi Olugemo, MD, Chief Medical Officer at Korro. “KRRO-110 has the potential to treat both liver and lung manifestations of AATD, and we are committed to addressing the unmet need and advancing this potentially best-in-class therapy for people living with AATD.”